Abstract
Myxopapillary ependymoma (MPE) is a rare subtype of ependymoma in children. Though classified as a Grade I tumor, their unpredictable behavior and propensity for local and disseminated recurrence poses a therapeutic challenge. Till date no predictive molecular markers exist for such recurrence, especially with dissemination. We demonstrated that Epidermal Growth Factor Receptor (EGFR) expression was seen in relapsed MPE both at diagnosis and at recurrence and none in the nonrecurring tumors. This finding suggests EGFR could be a predictive biomarker for recurrence in MPE. Pediatr Blood Cancer 2012;59:746-748.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 746-748 |
| Number of pages | 3 |
| Journal | Pediatric Blood and Cancer |
| Volume | 59 |
| Issue number | 4 |
| DOIs | |
| State | Published - Oct 2012 |
Keywords
- EGFR
- Myxopapillary ependymoma
- Prognostic marker
- Recurrence
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Hematology
- Oncology
Fingerprint
Dive into the research topics of 'EGFR as a predictor of relapse in myxopapillary ependymoma'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS